Navigation Links
News from Molecular Medicine
Date:5/20/2010

Cystic Fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

Manhasset, NY (Vocus) May 20, 2010 -- In the latest issue of Molecular Medicine, cystic fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

In other studies in the latest issue of Molecular Medicine, a team of Brazilian scientists tested the activity of a novel angiotensin converting enzyme (ACE) in thrombus formation in animals that were either hypertensive or not. They reported that the pharmacological activation of the ACE2 receptor with the experimental ligand reduced platelet attachment to vessels and thrombus formation. These results suggest that this could be a potential lead compound for the treatment of thrombogenic diseases.

Other findings in the journal include a pivotal discovery of immune regulation of cancer cells, an endogenous factor that works in wound healing, a gene therapy study on Fabry Disease, a study on the immunological properties at work in Celiac disease, and a new molecular fingerprint of lung injury.

Molecular Medicine is published by The Feinstein Institute for Molecular Research. The peer-reviewed journal strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. The journal, a bimonthly publication, serves as a forum through which scientists and researchers can communicate recent discoveries to a multi-disciplinary, international audience interested in understanding and curing disease.

To listen to the latest podcast on these studies visit www.molmed.org/podcast.html.

###

Read the full story at http://www.prweb.com/releases/Molecular-Medicine/cystic-fibrosis/prweb4017864.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular marker could help spot pancreatic cancer early
2. Molecular discovery points to new therapies for brain tumors
3. USC researchers discover new molecular subtype of brain cancer
4. The Association for Molecular Pathology celebrates ruling in DNA patent case
5. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
6. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
7. Molecular pathways linked to sex, age affect outcomes in lung cancer
8. Ground Breaking Molecular Diagnostics Business Appoints New CEO
9. Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantation
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. News from the Latest Issue of Molecular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
News from Molecular Medicine
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes ... a mock evacuation of the facility as part of a disaster drill on October ... Hose EMS and Shelton City Emergency Manager, as well as the Connecticut Long ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: